Alexion, AstraZeneca Rare Disease Shares Phase 3 Ultomiris Trial Results
BOSTON, Mass., July 27, 2026 Alexion, AstraZeneca Rare Disease announced high-level results from its global Phase 3 clinical program...
complement inhibitor
Advertisement
Nuvectis Pharma Announces China Approval of Ciprocopan for PNH
FORT LEE, N.J., July 23, 2026 Nuvectis Pharma, Inc. announced that ciprocopan (NXP100) has received marketing approval from China’s...
Novartis Fabhalta Wins Full FDA Approval for IgAN
BASEL, July 17, 2026 Novartis announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval for...
Alexion’s Ultomiris Gets FDA Priority Review for IgAN
BOSTON, US | June 15, 2026 Alexion, AstraZeneca Rare Disease announced that the U.S. Food and Drug Administration (FDA)...
AstraZeneca’s Ultomiris Shows Phase 3 Breakthrough in IgAN
Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...
Advertisements
FibroBiologics Advances Thymus Organoid Cancer Therapy
HOUSTON, Texas | April 10, 2026 FibroBiologics has unveiled promising preclinical data for its novel thymus organoid platform, demonstrating...
Sobi Gains Canada Approval for EMPAVELI Kidney Drug
WALTHAM, Massachusetts | April 9, 2026 Swedish Orphan Biovitrum (Sobi) has announced that Health Canada has approved EMPAVELI® (pegcetacoplan),...
Novartis Fabhalta® Slows Kidney Function Decline in Phase III IgAN Study
BASEL, Oct. 16, 2025 — Novartis announced positive final Phase III results from its APPLAUSE-IgAN trial, confirming that Fabhalta®...
Advertisement
